Lenvatinib 4 mg is a targeted cancer treatment that contains Lenvatinib as its active ingredient and is classified as a tyrosine kinase inhibitor (TKI). This treatment is aimed at different forms of cancer by inhibiting specific proteins (enzymes) that promote the development and persistence of cancer cells. Lenvatinib is frequently prescribed for individuals with advanced thyroid cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and endometrial carcinoma.

Lenvatinib targets several receptors that contribute to tumor progression and angiogenesis (the development of new blood vessels), aiding in the deceleration or cessation of cancer cell growth and enhancing outcomes for patients with advanced cancer.

Indications and Uses

Lenvatinib 4 mg is mainly utilized for:

Differentiated Thyroid Cancer (DTC): For patients experiencing locally recurrent or metastatic, progressive DTC that does not respond to radioactive iodine (RAI) therapy.

Renal Cell Carcinoma (RCC): Used with Everolimus for patients with advanced RCC following prior anti-angiogenic therapy.

Hepatocellular Carcinoma (HCC): As a primary treatment option for patients with unresectable HCC.

Endometrial Carcinoma: In conjunction with Pembrolizumab for patients with advanced endometrial carcinoma that is neither microsatellite instability-high (MSI-H) nor mismatch repair deficient (dMMR), and who have experienced disease progression after previous systemic therapy.

Be sure to speak with your oncologist to assess whether Lenvatinib is appropriate for you, given your medical history and current condition.

Mechanism of Action

Lenvatinib functions by blocking the activity of various receptor tyrosine kinases (RTKs), such as:

VEGFR 1–3 (Vascular Endothelial Growth Factor Receptors)

FGFR 1–4 (Fibroblast Growth Factor Receptors)

PDGFRα (Rezeptor alpha des plättchenabgeleiteten Wachstumsfaktors)

RET (Rearrangiert während der Transfektion)

KIT (Receptor for Stem Cell Factor)

These receptors play a role in crucial signaling pathways that regulate tumor angiogenesis and cell proliferation. Lenvatinib hinders the tumor’s capacity to form new blood vessels and aids the body’s attempts to stop cancer progression by obstructing these pathways.

Dosage and Administration

The Lenvatinib dosage varies based on the condition being treated, the patient’s weight, and whether it is administered alone or with other medications.

Usual HCC dosage: 8 mg daily for patients under 60 kg; 12 mg daily for those weighing 60 kg or more

For RCC (with Everolimus): Lenvatinib at a dosage of 18 mg taken orally once each day, in conjunction with Everolimus at a dosage of 5 mg once each day

For Endometrial Cancer (using Pembrolizumab): Lenvatinib at a dosage of 20 mg once a day, in conjunction with Pembrolizumab administered intravenously every three weeks

Always adhere to the dosage and schedule prescribed by your doctor. Lenvatinib should be administered daily at the same time, regardless of meals. The capsule must not be chewed or crushed.

Side Effects

Lenvatinib, similar to all medications, may lead to side effects. Typical side effects are:

High blood pressure (hypertension)

Müdigkeit

Durchfall

Reduced appetite

Vomiting or nausea

Reduction of weight

Joint and muscle aches

Stomatitis (mouth inflammation)

Serious but less frequent side effects may include:

Hepatic issues

Cardiac problems like QT prolongation

Kidney impairment

Proteinurie (erhöhter Proteingehalt im Urin)

Risk of bleeding or arterial thrombosis

Severe chest pain, ongoing vomiting, abnormal bleeding, or symptoms of an allergic reaction like rash, itching, or swelling require immediate medical attention if you experience them.

Precautions and Warnings

Pregnancy & Breastfeeding: Lenvatinib can be harmful to an unborn child and is not advised for use during pregnancy or breastfeeding. Effective contraception should be used by women of childbearing potential during treatment and for at least one month following the last dose.

Hepatic/Renal Impairment: Patients with liver or kidney dysfunction may require dose adjustments.

Drug Interactions: Lenvatinib may interact with other medications, including CYP3A inhibitors or inducers. Always notify your healthcare provider about all the medications you are currently using.

Storage Instructions

Lenvatinib 4 mg should be stored at room temperature (15°C to 30°C).

Store the medication in its original packaging

Shield from moisture and heat

Ensure children cannot reach it

Conclusion

Lenvatinib with a dosage of 4 mg is a powerful and hopeful treatment option for combating specific aggressive cancers. For patients who may not have succeeded with other treatment options, it provides hope and prolonged survival. Its application should always be overseen by a qualified oncologist because of its possible adverse effects and intricacy. To achieve the best results with this treatment, it is essential to monitor regularly, follow dosing schedules precisely, and manage side effects promptly.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What are the indications for Lenvatinib?
Lenvatinib 4 mg is employed in the treatment of specific cancer types, such as thyroid cancer, liver cancer (hepatocellular carcinoma), and kidney cancer (renal cell carcinoma). It functions by preventing cancer cells from proliferating and obstructing the blood supply to tumors.

2. What is the mechanism of action of Lenvatinib?
A tyrosine kinase inhibitor, lenvatinib. It inhibits certain proteins that encourage the proliferation of cancer cells and the formation of new blood vessels in tumors (angiogenesis). In this way, it slows or halts the growth of tumors.

3. What is the recommended way to take Lenvatinib 4 mg?
Lenvatinib should be taken once daily at the same time, irrespective of meals. The amount administered can differ based on the kind of cancer being addressed. Always adhere to your physician’s guidance.

4. Is it safe to take Lenvatinib while pregnant?
Lenvatinib is not advised during pregnancy because it can be harmful to the unborn child. Women of childbearing age should employ effective contraception while undergoing treatment and for at least one month following the final dose.

5. What is the duration of Lenvatinib treatment?
The length of treatment is contingent upon your body’s response to the medication and the manageability of side effects. The length of time you will use Lenvatinib will be decided by your doctor.

6. How should Lenvatinib 4 mg be stored correctly?
Keep Lenvatinib at room temperature, away from heat, humidity, and direct sunlight. Store it where children cannot access it and do not use it after the expiry date.